PDS Biotech aims to advance and expand its proprietary pipeline programs independently or in collaboration with renowned research institutions and pharmaceutical companies.
Key commercial partners:
Strategic Research Collaborations with:
PDS Biotech is dedicated to maximizing the full potential of the Versamune® and Versamune® plus PDS0301 platforms in oncology and the Infectimune® platform in infectious diseases.
Versamune® and Versamune® plus PDS0301 are proprietary T cell activating platform technologies which induce a strong immune response in combination with tailored antigens to fight cancer.
Infectimune® is a proprietary T cell immune activating platform technology designed to train the immune system to better protect against infectious diseases.
We are open to strategic partnerships which reflect the value-creating potential of our T cell activating platforms to provide performance-related downstream revenues, while preserving future growth opportunities for PDS Biotech.